VINS Bioproducts Limited, Hyderabad in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 clinical trials of VINCOV-19, India’s first antidote and cure against SARS-CoV-2 virus.
VINCOV-19 is now ready for market authorisation and for simultaneous Phase 3 clinical trials.
Phase 2 clinical trials were conducted across multiple centres in India and included over 200 patients. The Phase 2 clinical trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations.
Comments are closed.